Share on StockTwits

Receptos (NASDAQ:RCPT) Director S. Edward Torres unloaded 200,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was sold at an average price of $43.24, for a total transaction of $8,648,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Receptos (NASDAQ:RCPT) traded up 1.31% during mid-day trading on Friday, hitting $47.14. 394,883 shares of the company’s stock traded hands. Receptos has a 1-year low of $15.21 and a 1-year high of $55.00. The stock has a 50-day moving average of $40.6 and a 200-day moving average of $39.28. The company’s market cap is $1.286 billion.

Receptos (NASDAQ:RCPT) last released its earnings data on Tuesday, August 12th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.19. The company had revenue of $1.10 million for the quarter, compared to the consensus estimate of $1.28 million. Analysts expect that Receptos will post $-4.04 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Receptos in a research note on Wednesday. They set an “outperform” rating and a $60.00 price target on the stock. Separately, analysts at Nomura initiated coverage on shares of Receptos in a research note on Monday, June 30th. They set a “buy” rating and a $63.00 price target on the stock. Finally, analysts at BMO Capital Markets set a $58.00 price target on shares of Receptos in a research note on Tuesday, June 10th. Three investment analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $55.00.

Receptos, Inc (NASDAQ:RCPT) is a biopharmaceutical company.

Receive News & Ratings for Receptos Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Receptos Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.